24/7 Market News Snapshot 22 September, 2025 – Allarity Therapeutics, Inc. Common Stock (NASDAQ:ALLR)

September 22, 2025

DENVER, Colo., 22 September, 2025 (www.247marketnews.com) – (NASDAQ:ALLR) are discussed in this article.
Allarity Therapeutics, Inc. has demonstrated considerable momentum in the market, with its shares opening today at $1.56 and rising to $1.755, marking an increase of approximately 13.96%. This surge follows a previous close of $1.540, indicating strong investor interest and sentiment. The trading volume reached 1.58 million shares, suggesting active market engagement, which may reflect heightened liquidity and a potential upward trend for the stock. Traders are advised to monitor for possible resistance levels; sustained volume and continued positive movement could indicate a bullish outlook for the company in the near future.

Simultaneously, Allarity Therapeutics has made significant strides in oncology, presenting promising results in the treatment of advanced ovarian cancer at the recent American Association for Cancer Research (AACR) 7th Biennial Special Conference on Ovarian Cancer. In a presentation led by Dr. Jeremy Graff, the President and Chief Development Officer, data highlighted that patients with platinum-resistant and refractory ovarian cancer who received stenoparib (2X-121) showed a median Overall Survival (mOS) exceeding 25 months. This is an encouraging development for a patient population that typically faces bleak outcomes.

The analysis also indicated that two trial participants have remained on treatment for over 24 months, emphasizing the drug’s potential for extended survival regardless of BRCA genetic status. These results are particularly noteworthy as they exceed the 16-16.5 months of survival reported for the latest FDA-approved therapies. Not only does this align with the FDA’s emphasis on Overall Survival as a key endpoint, but it also reaffirms the unique therapeutic advantages of stenoparib, which operates as a dual inhibitor of PARP and the WNT pathway.

In light of these developments, CEO Thomas Jensen expressed a commitment to advancing stenoparib toward FDA approval, aiming to provide innovative treatment options for patients with limited alternatives. The company is actively enrolling participants in a new Phase 2 trial, reinforcing its dedication to addressing unmet medical needs in oncology and potentially transforming treatment landscapes.

Related news for (ALLR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.